Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias.
Otsuka H, Kita Y, Ito K, Sano T, Inokuchi J, Tomida R, Takahashi A, Matsumoto K, Kurahashi R, Ozaki Y, Uegaki M, Maruyama S, Mukai S, Tsutsumi M, Kawahara T, Segawa T, Kitamura H, Morita S, Kobayashi T. Otsuka H, et al. Among authors: matsumoto k. Cancer Sci. 2022 Nov;113(11):3912-3921. doi: 10.1111/cas.15539. Epub 2022 Sep 2. Cancer Sci. 2022. PMID: 35997546 Free PMC article.
Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Srinivas S, Morales-Barrera R, Carles J, Al-Wardat R, Al-Rabi K, Maakoseh M. Salah S, et al. Among authors: matsumoto k. Clin Genitourin Cancer. 2016 Jun;14(3):255-60. doi: 10.1016/j.clgc.2015.10.006. Epub 2015 Oct 24. Clin Genitourin Cancer. 2016. PMID: 26552764
Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies.
Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Vis DJ, Srinivas S, Morales-Barrera R, Carles J, Al-Rimawi D, Lee S, Kim KH, Izumi K, Lewin J. Salah S, et al. Among authors: matsumoto k. Clin Genitourin Cancer. 2017 Aug;15(4):e563-e571. doi: 10.1016/j.clgc.2016.12.014. Epub 2016 Dec 22. Clin Genitourin Cancer. 2017. PMID: 28065418
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R, Matsumoto K, Numakura K, Inokuchi J, Morizane S, Yoneyama T, Matsumura Y, Abe T, Inoue M, Yamada T, Terada N, Hirao S, Uemura M, Matsushita Y, Taoka R, Kobayashi T, Kojima T, Matsui Y, Kitamura H, Nishiyama H; Japanese Urological Oncology Group. Miyake M, et al. Among authors: matsumoto k. BMC Cancer. 2021 Mar 11;21(1):266. doi: 10.1186/s12885-021-07966-7. BMC Cancer. 2021. PMID: 33706705 Free PMC article.
Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.
Ito K, Kobayashi T, Kojima T, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Osaki Y, Tashiro Y, Uegaki M, Ogawa O, Kitamura H, Nishiyama H. Ito K, et al. Among authors: matsumoto k. Cancer Med. 2021 May;10(10):3188-3196. doi: 10.1002/cam4.3863. Epub 2021 May 1. Cancer Med. 2021. PMID: 33931987 Free PMC article.
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group. Kobayashi M, et al. BJU Int. 2022 Aug;130(2):226-234. doi: 10.1111/bju.15510. Epub 2021 Jul 6. BJU Int. 2022. PMID: 34110696
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Kato M, et al. Among authors: matsumoto k. Int J Urol. 2021 Dec;28(12):1261-1267. doi: 10.1111/iju.14686. Epub 2021 Sep 20. Int J Urol. 2021. PMID: 34545627
Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
Murakami Y, Matsumoto K, Miyake M, Amano N, Shimura S, Nishimura N, Iida K, Matsushita Y, Abe T, Yamada T, Uemura M, Matsui Y, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Iwamura M. Murakami Y, et al. Among authors: matsumoto k. Int J Urol. 2022 Oct;29(10):1195-1203. doi: 10.1111/iju.14976. Epub 2022 Jul 20. Int J Urol. 2022. PMID: 35858755
Gemcitabine-Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy.
Koguchi D, Matsumoto K, Ikeda M, Shimizu Y, Nakamura M, Shiono Y, Katsumata H, Sato Y, Iwamura M. Koguchi D, et al. Among authors: matsumoto k. Int J Mol Sci. 2022 Oct 11;23(20):12119. doi: 10.3390/ijms232012119. Int J Mol Sci. 2022. PMID: 36292976 Free PMC article.
10,313 results
You have reached the last available page of results. Please see the User Guide for more information.